GSE242290 1 V 0 GLUTATHIONE HUMAN DN (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE242290 1 V 0 GLUTATHIONE HUMAN DN.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE242290 1 V 0 GLUTATHIONE HUMAN DN.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE242290 1 V 0 GLUTATHIONE HUMAN DN.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE242290 1 V 0 GLUTATHIONE HUMAN DN.

Results found

Linked to

 

Label

Description

 

Gene

A-kinase anchoring protein 17A

Gene

NBPF member 26

Gene

interleukin 3 receptor subunit alpha

Gene

ribonuclease P subunit p21

Gene

transmembrane protein 271

Gene

spermatogenesis associated 25

Gene

protein kinase, membrane associated tyrosine/threonine 1

Gene

family with sequence similarity 222 member A

Gene

lysine methyltransferase 2B

Gene

shiftless antiviral inhibitor of ribosomal frameshifting

  • Gene

    A-kinase anchoring protein 17A



  • Gene

    interleukin 3 receptor subunit alpha


  • Gene

    ribonuclease P subunit p21


  • Gene

    transmembrane protein 271


  • Gene

    spermatogenesis associated 25


  • Gene

    protein kinase, membrane associated tyrosine/threonine 1


  • Gene

    family with sequence similarity 222 member A


  • Gene

    lysine methyltransferase 2B


  • Gene

    shiftless antiviral inhibitor of ribosomal frameshifting

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.